Guest Editor
Collection Overview
Cannabinoid exposure in humans continues to increase. Historically, their use remains illegal at the federal level, and with cannabinoid products currently being classified as Schedule I drugs, access to the chemical for researchers has been challenging and has inhibited research in this area. A recent proposal may reclassify cannabinoid products as Schedule III drugs, potentially easing access for researchers. Of particular concern is the impact of cannabinoid exposure on fetal development during pregnancy.
Consequently, this Methods Collection will focus on methodologies for cannabinoid exposure in animal models, including prenatal exposure models. As utilization continues to increase in the United States, quality research in this field is desperately needed. A collection focused on this important topic would support the standardization of the approaches, a crucial step in advancing our understanding of cannabinoid exposure.
Articles
Development of a Preclinical Inhalation Model to Test Vaporized Cannabis Distillates
0 Views
•
Cited by 1
•
2025
•
1Meakins-Christie Laboratories, 2Translational Research in Respiratory Diseases Program at the Research Institute of the McGill University Health Centre, McGill University, 3Department of Pathology, McGill University, 4Department of Bioresource Engineering, McGill University, 5Department of Medicine, McGill University, 6Department of Pharmacology and Therapeutics, McGill University
